FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of June 2017
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X
Form
40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __ No
X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule
12g3-2(b): 82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
ASTRAZENECA PRICES
A $2BN BOND ISSUE
6 June
2017 07:00 BST
ASTRAZENECA PRICES A $2BN BOND ISSUE
AstraZeneca
PLC announces that, on 5 June 2017, it priced a three tranche
Global bond offering totalling $2bn. The offering is expected to
close on 12 June 2017, subject to customary closing conditions.
AstraZeneca expects to use the net proceeds of the issue for
general corporate purposes which may include the refinancing of
existing indebtedness. The transaction, which is a global offering
registered with the US Securities and Exchange Commission (SEC),
consists of the following three tranches:
●
$1bn of 5 year fixed rate notes with a coupon of
2.375%;
●
$0.75bn of 10 year fixed rate notes with a coupon of 3.125%;
and
●
$0.25bn of 5 year floating rate notes.
Barclays,
BofA Merrill Lynch, HSBC and Morgan Stanley acted as
joint-bookrunning managers on the transaction. The notes will be
issued under AstraZeneca's effective shelf registration statement
on Form F-3, which AstraZeneca filed with the SEC on 22 November
2016. The offering is being made solely by means of the prospectus
contained within that shelf registration statement, along with a
prospectus supplement forming part of the effective registration
statement, which investors should read.
A copy
of the prospectus supplement and accompanying prospectus relating
to the offering can be obtained by contacting Barclays Capital Inc.
c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, by telephone at 1-888-603-5847 or by email at
[email protected];
HSBC Securities (USA) Inc., 452 Fifth Avenue, New York, NY 10018,
Attention: Transaction Management Group, by telephone at
1-866-811-8049; Merrill Lynch, Pierce, Fenner & Smith
Incorporated, NC1-004-03-43, 200 North College Street, 3rd floor,
Charlotte NC 28255-0001, Attention: Prospectus Department, by
telephone at 1-800-294-1322 or by email at [email protected];
or Morgan Stanley & Co. LLC, Attention: Prospectus Department,
180 Varick Street, 2nd Floor, New York, NY 10014, by telephone at
1-866-718-1649 or by email at [email protected].
You may also download these documents for free by visiting EDGAR on
the SEC website at www.sec.gov.
This
announcement shall not constitute an offer to sell or the
solicitation of an offer to buy the securities described herein,
nor shall there be any sale of these securities in any jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any
such jurisdiction.
The
bond issuance does not impact the Company's financial guidance for
2017.
About AstraZeneca
AstraZeneca
is a global, science-led biopharmaceutical company that focuses on
the discovery, development and commercialisation of prescription
medicines, primarily for the treatment of diseases in three main
therapy areas - Oncology, Cardiovascular & Metabolic Diseases
and Respiratory. The Company also is selectively active in the
areas of autoimmunity, neuroscience and infection. AstraZeneca
operates in over 100 countries and its innovative medicines are
used by millions of patients worldwide.
Cautionary Statements Regarding Forward-Looking
Statements
This
announcement contains certain forward-looking statements with
respect to the operations, performance and financial condition of
AstraZeneca. Although we believe our expectations are based on
reasonable assumptions, any forward-looking statements, by their
very nature, involve risks and uncertainties and may be influenced
by factors that could cause actual outcomes and results to be
materially different from those predicted. The forward-looking
statements reflect knowledge and information available at the date
of preparation of this announcement and AstraZeneca undertakes no
obligation to update these forward-looking statements.
|
Media Relations
|
|
|
|
Esra
Erkal-Paler
|
UK/Global
|
+44 203
749 5638
|
|
Karen
Birmingham
|
UK/Global
|
+44 203
749 5634
|
|
Rob
Skelding
|
UK/Global
|
+44 203
749 5821
|
|
Jacob
Lund
|
Sweden
|
+46 8
553 260 20
|
|
Michele
Meixell
|
US
|
+1 302
885 2677
|
|
Investor Relations
|
|
|
|
Thomas
Kudsk Larsen
|
|
+44 203
749 5712
|
|
Craig
Marks
|
Finance,
Fixed Income, M&A
|
+44
7881 615 764
|
|
Henry
Wheeler
|
Oncology
|
+44 203
749 5797
|
|
Mitchell
Chan
|
Oncology
|
+1 240
477 3771
|
|
Lindsey
Trickett
|
Cardiovascular
& Metabolic Diseases
|
+1 240
543 7970
|
|
Nick
Stone
|
Respiratory
|
+44 203
749 5716
|
|
Christer
Gruvris
|
Autoimmunity,
Neuroscience & Infection
|
+44 203
749 5711
|
|
US toll
free
|
|
+1 866
381 7277
|
Adrian Kemp
Company Secretary, AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
AstraZeneca
PLC
|
Date:
06 June 2017
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|